Author

Yixie Zhang

Observed name: Zhang, Yixie

Institution: EVERSANA (Canada)

Observed institutions: University of Toronto, EVERSANA (Canada)

ORCID: 0000-0002-5346-7662

Observed ORCID: 0000-0002-5346-7662

OpenAlex ID: A5036019538

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

2021 · David G. Maloney, John Kuruvilla, et al. · Journal of Hematology & Oncology · 61

Collision of Expanding Actin Caps with Actomyosin Borders for Cortical Bending and Mitotic Rounding in a Syncytium

2018 · Yixie Zhang, Jessica C. Yu, et al. · Developmental Cell · 35

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

2022 · Guillaume Cartron, Christopher P. Fox, et al. · Experimental Hematology and Oncology · 27

Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review

2023 · Melody Zhao, Kent A. Hanson, et al. · Targeted Oncology · 14

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

2020 · David G. Maloney, John Kuruvilla, et al. · Blood · 11

Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma

2025 · Jeremy S. Abramson, Manali Kamdar, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

2022 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 3

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

2024 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 2

Po-06-223 the Budget Impact Associated With Increased Use of Long-term Electrocardiogram Monitors for the Detection of Arrhythmias in the United States

2025 · Susan Eisenberg, Jessica Coughlin, et al. · Heart Rhythm

Cell Topology Change by the Physical Engagement of Neighboring Cytoskeletal Networks

2018 · Yixie Zhang · TSpace (University of Toronto)

Organizing Complex Tissue Architecture by Pushing and Pulling Cell Contacts

2018 · Yixie Zhang, Tony J.C. Harris · Developmental Cell

Works count: 15

Citation count: 158

H-index: 5

I10-index: 5